We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Edesa Biotech Inc (EDSA) NPV

Sell:$4.20 Buy:$4.46 Change: $0.0485 (1.09%)
Market closed |  Prices as at close on 26 April 2024 | Switch to live prices |
Sell:$4.20
Buy:$4.46
Change: $0.0485 (1.09%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 April 2024 | Switch to live prices |
Sell:$4.20
Buy:$4.46
Change: $0.0485 (1.09%)
Market closed |  Prices as at close on 26 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. In addition, the Company is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic allergic contact dermatitis (ACD), a common occupational skin condition. It is conducting a Phase II trial of its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The Company is also developing product candidates for a number of chronic dermatological and inflammatory conditions.

Contact details

Address:
100 Spy Crt
MARKHAM
L3R 5H6
Canada
Telephone:
+1 (905) 4751234
Website:
https://www.edesabiotech.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EDSA
ISIN:
CA27966L3065
Market cap:
$14.21 million
Shares in issue:
3.22 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Canada
Currency:
US dollar
Indices:
n/a

Key personnel

  • Michael Brooks
    President
  • Pardeep Nijhawan
    Chief Executive Officer, Corporate Secretary, Director
  • Stephen Lemieux
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.